EMBC Embecta Corp. NASDAQ · United States

Embecta (EMBC) news

Embecta Corp. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker EMBC, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Embecta news

We have not published a story on Embecta yet. When there is news, it will appear here.

Embecta annual financials

Line	FY ended Sep 30, 2025	FY ended Sep 30, 2024
Revenue	$1.08 billion	$1.12 billion
Research and development	$37.3 million	$78.8 million
Net income (loss)	$95.4 million	$78.3 million
Cash from operations	$191.7 million	$35.7 million
Cash and equivalents	$225.5 million	$267.5 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $214.7 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Embecta

What is the ticker symbol of Embecta?

Embecta Corp. trades under the ticker EMBC on NASDAQ.

Where is Embecta listed?

Embecta Corp. is listed on NASDAQ.

Which country or territory is Embecta listed under?

Our directory records Embecta Corp. under United States.

Does aibio.space cover Embecta?

aibio.space lists Embecta Corp. among 2,820 public biotech companies and publishes its news here as stories appear.

What was Embecta's revenue last year?

$1.08 billion for the fiscal year ended Sep 30, 2025, as reported to the SEC.

Is Embecta profitable?

Embecta Corp. reported net income of $95.4 million for the fiscal year ended Sep 30, 2025, and generated $191.7 million of cash from operations, per its annual report to the SEC.

How much does Embecta spend on research and development?

$37.3 million in the fiscal year ended Sep 30, 2025, per its annual report.

How much cash does Embecta have?

$214.7 million in cash at Jun 30, 2026, per its 10-Q.

Investor discussion: Embecta

Members talk about Embecta (EMBC). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Embecta, newest first. Each line links the filing it comes from.

Aug 7, 2026Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
May 15, 2026Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:EMBC on TradingView.

Listing details

Company: Embecta Corp.
Ticker: EMBC
Listing: NASDAQ
Country or territory: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction